Investors Archives - Page 2 of 2

Zogenix’s seizure drug filing fails to pass U.S. FDA scrutiny

Dravet syndrome, Epilepsy, FDA, FDA/Regulatory, Investors, Refusal to File letter, Seizures, Shares

The FDA refused to fully review the marketing application for Zogenix’s treatment for seizures associated with Dravet syndrome.

April 8, 2019/by Reuters Health

New White Paper Helps Ambulatory Surgical Centers Understand the Ins and Outs of ASC Marketing

Consumers, Healthcare Communications Agencies, Investors, Marketing & Advertising, Surgical Centers, White Papers

The white paper from moddern marketing provides five core principles to help ASC owners and investors understand marketing and healthcare consumers. NEW YORK (PRWEB) February 11, 2019 moddern […]

February 11, 2019/by Administrator

Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication

Breakthrough Therapy Status, Clinical Data, Fast Track Designation, FDA, Head & Neck Cancer, Investors

Galera Therapeutics Inc.announced that the clinical-stage biotechnology company secured $150 million in a joint, oversubscribed Series C financing and royalty purchase agreement.

September 19, 2018/by GlobeNewswire

Syneos Health Acquires Kinapse

Biopharmaceutical, Business, Contract Commercial Organization (CCO), Contract Research Organization (CRO), CRO, Investors, Life Sciences

Syneos Health Inc. announced the acquisition of Kinapse – a market leading advisory and operational solutions provider to the global life sciences industry – from Hg, a specialist investor based in the U.K.

August 20, 2018/by GlobeNewswire